Street taps Epocrates for research
The research arm of investment banking firm Goldman Sachs will look to promote Epocrates' marketing research services. Financial terms of the three-year agreement were not disclosed.
Hudson Street, a Goldman Sachs business, will seek to connect Epocrates to buyside investors and portfolio managers for use in investigating potential pharma and biotech investments.
“We have a highly targeted panel that they can reach,” said Kirk Loevner, Epocrates chairman and chief executive officer.
Epocrates claims 500,000 active clinician users in its subscriber base. Of those, 200,000 are active US physicians, and 145,000 of those have opted into the marketing research service.Epocrates, also known for its clinical information and decision support tools, already works with about 150 marketing research firms. They are drawn to the vendor's ability to tap into its physician panel, by specialty and by geography, and get answers to surveys.